100,000 Shares in Immunome, Inc. $IMNM Acquired by Zimmer Partners LP

Key Points

• Zimmer Partners LP acquired a new stake in Immunome, Inc. worth approximately $673,000, purchasing 100,000 shares in the first quarter.
• Immunome's stock has been rated a "buy" by multiple analysts, with a consensus target price of $22.89, reflecting positive sentiment about the company's growth potential.
• The company reported a revenue of $4.02 million for the last quarter, exceeding analyst estimates significantly, despite a negative EPS of ($0.50).

Zimmer Partners LP bought a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 100,000 shares of the company's stock, valued at approximately $673,000. Zimmer Partners LP owned 0.11% of Immunome as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets purchased a new position in Immunome in the 4th quarter worth $70,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Immunome in the first quarter valued at about $95,000. KLP Kapitalforvaltning AS increased its position in shares of Immunome by 140.8% in the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock valued at $115,000 after acquiring an additional 10,000 shares during the period. Teacher Retirement System of Texas increased its position in shares of Immunome by 49.0% in the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company's stock valued at $117,000 after acquiring an additional 5,712 shares during the period. Finally, Arizona State Retirement System increased its position in shares of Immunome by 66.2% in the first quarter. Arizona State Retirement System now owns 18,764 shares of the company's stock valued at $126,000 after acquiring an additional 7,476 shares during the period. Hedge funds and other institutional investors own 44.58% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on IMNM. Guggenheim restated a "buy" rating and issued a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. Craig Hallum assumed coverage on shares of Immunome in a research note on Friday, September 5th. They set a "buy" rating and a $26.00 target price on the stock. Evercore ISI assumed coverage on shares of Immunome in a research note on Friday, August 22nd. They set an "outperform" rating and a $18.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and set a $21.00 target price on shares of Immunome in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. cut their target price on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $22.89.

Immunome Stock Down 0.3%

Shares of NASDAQ IMNM traded down $0.02 during midday trading on Monday, hitting $9.19. The stock had a trading volume of 301,672 shares, compared to its average volume of 1,014,172. The business's 50 day moving average is $9.94 and its 200-day moving average is $8.83. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $16.73. The company has a market cap of $799.55 million, a P/E ratio of -2.99 and a beta of 1.92.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The business had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. As a group, analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.